HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


“Confusing” Green Tea Qualified Health Claims Need New Wording – Petition

This article was originally published in The Tan Sheet

Executive Summary

FDA should modify approved qualified health claims for the link between green tea and certain cancers, according to a petition from green tea marketer Fleminger

You may also be interested in...

FDA Allows Claims Linking Calcium with Hypertension, Colon/Rectal Cancer

FDA will allow qualified health claims linking supplemental calcium intake to a decreased risk of hypertension, the agency announces Oct. 12

Qualified Claims Language And Grading Confuses Consumers – FDA Study

"Report card grade disclaimers" used to distinguish the amount of scientific evidence backing a health claim may cause consumers to be more skeptical of the science behind unqualified health claims compared to qualified claims, according an FDA survey

Green Tea Cancer Prevention Claims Offered By FDA Stress Data Limits

FDA emphasizes the negative in its specified wording for qualified health claims that may link green tea with prevention of breast and prostate cancers

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts